protein kinase C betaGenealiases: PKC-beta · PKCB · PKCI(2) · PKCbeta · PRKCB1 · PRKCB2
Q-omics provides the consensus-scored PRKCB profile across patient tissues and cancer cell-line models. PRKCB expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, PRKCB is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, PRKCB protein abundance shows 31,233 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LUAD, BLCA, and GBM as cancer lineages where PRKCB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRKCB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRKCB survival associations across molecular data types. PRKCB RNA expression shows survival associations in the most cancer types (28), followed by mutation status (10) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRKCB RNA expression–survival associations across cancer types. High PRKCB expression shows favorable associations in LUAD, HNSC, CESC, BRCA, LGG and SARC. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for PRKCB RNA expression.
This table summarizes PRKCB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in BLCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PRKCB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRKCB shows lower tumor expression in BLCA, COAD, LUSC, LUAD and KICH and higher tumor expression in KIRC. The BLCA box plot shows higher PRKCB RNA expression in normal versus tumor tissue (log2 FC = −2.897, t-test p < 0.001).
This table shows molecular features associated with PRKCB in patient tissues and cancer cell lines. In patient samples, PRKCB shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PRKCB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BONE.
